成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

返回ChemicalBook首頁(yè)>CAS數(shù)據(jù)庫(kù)列表>1253186-56-9

1253186-56-9

中文名稱(chēng) 1253186-56-9
英文名稱(chēng) GSK-7975A
CAS 1253186-56-9
分子式 C18H12F5N3O2
分子量 397.3
MOL 文件 1253186-56-9.mol
更新日期 2024/10/28 11:14:31
1253186-56-9 結(jié)構(gòu)式 1253186-56-9 結(jié)構(gòu)式

基本信息

中文別名
化合物GSK-7975A
2,6-二氟-N-[1-[[4-羥基-2-(三氟甲基)苯基]甲基]-1H-吡唑-3-基]苯甲酰胺
英文別名
GSK-7975A
2,6-Difluoro-N-(1-{[4-hydroxy-2-(trifluoromethyl)phenyl]methyl} 1H-pyrazol-3-yl)benzamide
Benzamide, 2,6-difluoro-N-[1-[[4-hydroxy-2-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-3-yl]-

物理化學(xué)性質(zhì)

沸點(diǎn)462.2±45.0 °C(Predicted)
密度1.46±0.1 g/cm3(Predicted)
儲(chǔ)存條件Sealed in dry,2-8°C
溶解度DMSO:90.0(Max Conc. mg/mL);226.53(Max Conc. mM)
酸度系數(shù)(pKa)8.82±0.20(Predicted)
形態(tài)Solid
顏色White to off-white

安全數(shù)據(jù)

危險(xiǎn)性符號(hào)(GHS)GHS hazard pictograms
GHS07
警示詞警告
危險(xiǎn)性描述H302-H315-H319-H335
防范說(shuō)明P261-P305+P351+P338

常見(jiàn)問(wèn)題列表

生物活性
GSK-7975A是高效有口服活性的 CRAC 通道抑制劑。
體外研究

GSK-7975A reduces FcεRI-dependent Ca 2+ influx and 3 μM GSK-7975A reduces the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα) by up to 50%. GSK-7975A inhibits mediator release from mast cells, and pro-inflammatory cytokine release from T-cells in a variety species. GSK-7975A completely inhibits calcium influx through CRAC channels. This leads to inhibition of the release of mast cell mediators and T-cell cytokines from multiple human and rat preparations. Mast cells from guinea-pig and mouse preparations are not inhibited by GSK-7975A; however cytokine release is fully blocked from T-cells in a mouse preparation. GSK-7975A inhibits toxin-induced activation of ORAI1 and/or activation of Ca 2+ currents after Ca 2+ release, in a concentration-dependent manner, in mouse and human pancreatic acinar cells (inhibition >90% of the levels observed in control cells). GSK-7975A also prevents activation of the necrotic cell death pathway in mouse and human pancreatic acinar cells.

體內(nèi)研究

GSK-7975A inhibits local and systemic features of acute pancreatitis in TLCS-AP, CER-AP, FAEE-AP, in dose- and time-dependent manners. GSK-7975A significantly reduces increases in serum amylase, IL6, and pancreatic MPO levels; lung MPO is reduced significantly by low dose only. GSK-7975A markedly reduces pancreatic histopathology in TLCS-AP, CER-AP, and FAEE-AP.

"1253186-56-9" 相關(guān)產(chǎn)品信息